Evelo Biosciences (EVLO) Competitors $0.0005 0.00 (0.00%) As of 09/8/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EVLO vs. SCPS, SMFL, VRPX, STAB, CMRA, GNCAQ, GNCA, ARDS, AMPE, and HSTOShould you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Scopus BioPharma (SCPS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), and Histogen (HSTO). These companies are all part of the "pharmaceutical products" industry. Evelo Biosciences vs. Its Competitors Scopus BioPharma Smart for Life Virpax Pharmaceuticals Statera Biopharma Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals Histogen Evelo Biosciences (NASDAQ:EVLO) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation. Do insiders & institutionals believe in EVLO or SCPS? 0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, EVLO or SCPS? Evelo Biosciences has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Does the media favor EVLO or SCPS? In the previous week, Evelo Biosciences had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Scopus BioPharma. Evelo Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Evelo Biosciences Neutral Scopus BioPharma Neutral Which has better valuation and earnings, EVLO or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvelo BiosciencesN/AN/A-$114.53MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Is EVLO or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Evelo BiosciencesN/A N/A N/A Scopus BioPharma N/A N/A N/A SummaryEvelo Biosciences beats Scopus BioPharma on 3 of the 5 factors compared between the two stocks. Get Evelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart EVLO vs. The Competition Export to ExcelMetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9K$925.73M$5.81B$10.03BDividend YieldN/A4.84%6.67%4.54%P/E RatioN/A1.1675.7526.29Price / SalesN/A26.96449.5181.86Price / CashN/A19.5625.7029.20Price / BookN/A6.7511.506.43Net Income-$114.53M-$4.20M$3.28B$270.56M7 Day PerformanceN/A1.54%1.30%3.01%1 Month PerformanceN/A8.71%11.25%9.74%1 Year PerformanceN/A27.10%59.54%26.68% Evelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120SCPSScopus BioPharmaN/A$0.00+33.3%N/A+0.0%$17KN/A0.009SMFLSmart for LifeN/A$0.00+100.0%N/A-99.6%$16K$11.11M0.00110Gap DownVRPXVirpax Pharmaceuticals0.1041 of 5 stars$0.01flatN/A-99.9%$14KN/A0.007STABStatera BiopharmaN/A$0.00+100.0%N/A-83.3%$11KN/A0.0020Gap UpHigh Trading VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00-99.8%N/AN/A$5KN/A0.0030Gap DownAMPEAmpio PharmaceuticalsN/A$0.00-96.8%N/A+22.7%$3KN/A0.0020Gap DownHSTOHistogenN/A$0.00+66.7%N/A-99.9%$2K$19K0.0020 Related Companies and Tools Related Companies SCPS Alternatives SMFL Alternatives VRPX Alternatives STAB Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives ARDS Alternatives AMPE Alternatives HSTO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVLO) was last updated on 9/9/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
